Current News

Print version | PDF version | Send article | RSS-Feed

BAC and Octapharma to develop custom ligand for recombinant plasma protein

18 Mar 2008 - BAC BV announced that it has entered into a collaboration with Octapharma AG. The objective of the collaboration is to discover and develop a custom CaptureSelect(r) ligand for the purification of a recombinant Factor IX product, developed by Octapharma for the prophylaxis and treatment of bleeding in Haemophilia B. Octapharma will use the CaptureSelect ligand in the downstream processing of this protein from mammalian cell lines.
 
"We have proven that we can design ligands for almost any purification challenge," commented Laurens Sierkstra, CEO of BAC. "Our technology platform enables us to work with our partners to produce affinity media that is custom designed for each individual purification target, meaning that our customers can have absolute confidence that their purification process will be a success. We are very much looking forward to working with Octapharma on this project."